Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 GeneticVariation group BEFREE An increase of 0.1 in NDVI corresponded to a reduction in SBP of 1.39 mmHg (95% CI: 1.86, -0.93) and lower odds of hypertension (OR = 0.76, 95% CI: 0.69, 0.82). 31672364 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 GeneticVariation group BEFREE We used inverse variance weighting (IVW) to assess the relation of HbA1c with risk of hypertension (defined using the American College of Cardiology/American Heart Association 2017 guidelines), and SBP and DBP. 31386636 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 GeneticVariation group BEFREE Epidemiological studies reported an inconsistent association between stage 1 hypertension (SBP 130-139 mmHg or DBP 80-89 mmHg) defined by the 2017 American College of Cardiology/American Heart Association hypertension guidelines and cardiovascular disease (CVD) events. 31790053 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE One-year hypertension remission and SBP and DBP pressure change at 1 and 5 years after both surgical techniques were also evaluated. 31633582 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 GeneticVariation group BEFREE Stage 2 hypertension (SBP/DBP ≥ 140/90 mmHg) showed significant associations with cardiovascular disease and all-cause mortality, while elevated blood pressure (SBP 120-129 mmHg and DBP < 80 mmHg) showed null associations. 31288541 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE To obtain inter-arm differences of SBP (the absolute difference of right and left arm) and ankle-brachial index, bilateral blood pressures were measured simultaneously at the four limbs using an automated oscillometric device in patients with treated hypertension (n = 234) and in normotensive subjects (n = 40). 31714348 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 GeneticVariation group BEFREE Patients with high Hcy and MTHFR 667CC, as well as those with low Hcy and 667CT+TT, showed lower odds of uncontrolled SBP (MTHFR 667CC+ high Hcy: OR: 0.338, 95% CI: 0.115-0.996, Pcombined = 0.049; MTHFR 667CT/TT+ low Hcy: OR: 0.421, 95% CI: 0.193-0.921, Pcombined = 0.030) compared to patients with low Hcy and MTHFR 667CC.<b>Conclusions</b>: Serum Hcy status and Hcy metabolism gene polymorphisms (MTHFR C667T and MTRR A66G) may have synergistic effects on the prevalence of HTN and dyslipidemia. 30786773 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 GeneticVariation group BEFREE For subjects (n = 50) who exhibited uncontrolled morning hypertension (home systolic blood pressure [SBP]≥125 mmHg) at the end of study period I (at 8 weeks), nifedipine CR (20-40 mg) was added at bedtime, and rivaroxaban administration was continued an additional 8 weeks. 31542950 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Participants with hypertension but without diabetes (N = 1167) were randomized to an SBP target below 120 mm Hg (intensive treatment) vs a target below 140 mm Hg (standard treatment). 31840813 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Systolic and diastolic blood pressure (SBP and DBP), and pulse pressure (PP), low-density lipoprotein cholesterol and triglyceride levels, RRI, RPI, kidney length, IVSd, PWd, and LVMI were significantly higher in patients with HT (both p < 0.05). 30285504 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE In a univariate logistic regression analysis hypertension and clinic SBP were not associated with revealed symptoms. 31157741 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 GeneticVariation group BEFREE This randomized-cross-over study included 38 patients (age: 60.4 ± 11.1 years, male: 65.8%) with intradialytic hypertension (intradialytic-SBP increase ≥ 10 mmHg at ≥4 over 6 consecutive sessions). 30622317 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Hypertension was defined as SBP at least 130 mmHg or DBP at least 80 mmHg, taking antihypertensive medicine or self-report. 31356404 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Recent hypertension guidelines endorsed SBP targets below 130 or lower for all or some hypertensive patients to reduce cardiovascular events (CVEs) more than the prior SBP target less than 140. 30624370 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Multiple linear regression analysis revealed that baseline ABI was positively and independently associated with the yearly change in brachial SBP and hypertension incidence. 30640883 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Childhood hypertension and elevated blood pressure were defined as SBP and/or DBP ≥95th and ≥90th age- and gender-specific percentile, respectively. 31826379 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Cox proportional hazards regression revealed that SBP (1.02[1.01, 1.02]) and more insomnia symptoms (1.11[1.01, 1.21]) were significant predictors of hypertension for all age groups. 30742871 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE These trials - SPYRAL OFF-MED, RADIANCE SOLO and SPYRAL ON-MED - using newer technologies, demonstrate a 5-10 mmHg incremental reduction in ambulatory SBP from RDN against sham-control, in patients with mild-to-moderate hypertension taking 0-3 drugs. 31268917 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE The impact of SBP changes on eGFR was not significant; however, studies were of a relatively short duration.<b>Conclusion:</b> ARB had a favorable impact on BP and renal parameters such as proteinuria with monotherapy as well as with combination therapy, highlighting their potential benefits in patients with hypertension and CKD. 31392910 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE We analyzed OH measurements from the Action to Control Cardiovascular Risk in Diabetes BP trial, which evaluated two blood pressure (BP) goals (systolic BP [SBP] < 120 mm Hg vs. SBP < 140 mm Hg) and incident CVD among adults with diabetes and hypertension. 30715100 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 AlteredExpression group BEFREE Mapuche and European schoolchildren show higher levels of SBP with a decrease in sleep time of 30 min; however, there is a higher prevalence of hypertension and obesity in ethnic Mapuches than in European schoolchildren. 31361065 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Further logistic analysis indicated that the irisin level was positively correlated with SBP and an independent predictor for hypertension after adjustment. 31133682 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 AlteredExpression group BEFREE The PLR had an inverse relationship with the degree of hypertension; SBP p value of 0.0001, while DBP was p = 0.0001. 30835575 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE We defined hypertension as SBP of 140 mmHg or less and/or DBP of at least 90 mmHg, according to the 2010 Chinese guidelines for the management of hypertension. 30817449 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Our aim was to assess the impact of cumulative SBP and SAEs on intensive hypertension treatment efficacy in the Systolic Blood Pressure Intervention Trial (SPRINT) population during follow-up. 30444838 2019